ÀǾàǰ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ °øµ¿°³¹ß °Å·¡(2016-2025³â)
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2025
»óǰÄÚµå : 1696304
¸®¼­Ä¡»ç : Current Partnering, a brand of Biopharma Research Ltd.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 450+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,995 £Ü 5,780,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,995 £Ü 8,674,000
PDF (Multi User License - 2 to 5 Users) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2-5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,995 £Ü 11,567,000
PDF (Company Wide License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀǾàǰ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÐ¾ßÀÇ °øµ¿°³¹ß ÇÁ·ÎÁ§Æ®´Â ±â¾÷ÀÌ °øµ¿°³¹ß ÇÁ·ÎÁ§Æ®¿¡ Âü¿©ÇÏ´Â ¹æ¹ý°ú ÀÌÀ¯¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀÌÇØ¿Í ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

º» º¸°í¼­´Â 2016³âºÎÅÍ 2025³â±îÁöÀÇ °øµ¿°³¹ß °Å·¡¿¡ ´ëÇÑ ¼¼ºÎ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ´ç»çÀÚ °£¿¡ ¹ßÇ¥µÈ °øµ¿°³¹ß °Å·¡ÀÇ ÁöºÒ Á¶°Ç¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÁöºÒ Á¶°Ç ¹× ±âŸ °Å·¡ Á¶°Ç¿¡ ´ëÇÑ À¯¿ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

ÆÄÆ®³Ê Èĺ¸ÀÚ°¡ Çù»óÇÑ °Å·¡ Á¶°ÇÀÇ À¯¿¬¼ºÀ» ÀÌÇØÇϸé Çù»ó °úÁ¤¿¡¼­ ¹«¾ùÀ» ±â´ëÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¸¹Àº Áß¼Ò±â¾÷Àº ÁöºÒ Á¶Ç×ÀÇ ¼¼ºÎ »çÇ×À» ¿ä±¸ÇÒ °ÍÀÌÁö¸¸, ÁöºÒÀÇ ¹ßµ¿ ¹× ±Ç¸® ÀÌÀü ¹æ¹ý¿¡ ´ëÇØ¼­´Â ¼¼ºÎ »çÇ׿¡ ¾Ç¸¶°¡ ¼û¾î ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡´Â 2016³â ÀÌÈÄ ¹ßÇ¥µÈ °øµ¿°³¹ß °Å·¡¿¡ ´ëÇØ Current AgreementsÀÇ °Å·¡/Á¦ÈÞ µ¥ÀÌÅͺ£À̽º¿¡ ±â·ÏµÈ ³»¿ëÀ» Æ÷°ýÀûÀ¸·Î ³ª¿­Çϰí, °¡´ÉÇÑ °æ¿ì À繫Á¶°ÇÀ» Æ÷ÇÔÇϸç, ±â¾÷°ú ±× ÆÄÆ®³Ê°¡ Áõ±Ç°Å·¡À§¿øÈ¸¿¡ Á¦ÃâÇÑ ½ÇÁ¦ °øµ¿°³¹ß °Å·¡ ¹®¼­ÀÇ ¿Â¶óÀÎ »çº»¿¡ ´ëÇÑ ¸µÅ©µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­ÀÇ Ã¹ ¹øÂ° Àå¿¡¼­´Â °øµ¿°³¹ß °Å·¡¿Í »ç¾÷ Ȱµ¿¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.

1Àå¿¡¼­´Â º» º¸°í¼­ÀÇ ¼Ò°³¸¦ Á¦°øÇϰí, 2Àå¿¡¼­´Â °øµ¿°³¹ß µ¿Çâ¿¡ ´ëÇÑ °³¿ä¿Í ºÐ¼®, ±×¸®°í °Å·¡ À¯ÇüÀÇ ÀåÁ¡¿¡ ´ëÇÑ ³íÀǸ¦ Á¦°øÇÕ´Ï´Ù.

3Àå¿¡¼­´Â °øµ¿°³¹ß ¾È°ÇÀÇ ±¸Á¶¿¡ ´ëÇØ °³°ýÀûÀ¸·Î »ìÆìº¾´Ï´Ù.

4Àå¿¡¼­´Â 2016³â ÀÌÈÄ ´ëÇ¥ÀûÀÎ °øµ¿°³¹ß ¾È°ÇÀ» °ËÅäÇÕ´Ï´Ù. ¾È°ÇµéÀº Çìµå¶óÀÎ ±Ý¾×º°·Î ³ª¿­µÇ¾î ÀÖ½À´Ï´Ù. SEC¿¡ °ø½ÃµÈ °è¾à¼­°¡ ÀÖ´Â °æ¿ì, Current Agreements deals and alliances µ¥ÀÌÅͺ£À̽º¸¦ ÅëÇØ °è¾à¼­¿¡ ´ëÇÑ ¿Â¶óÀÎ ¾×¼¼½º¸¦ Á¦°øÇÏ´Â ¸µÅ©¸¦ Á¦°øÇÕ´Ï´Ù.

5Àå¿¡¼­´Â °¡Àå Ȱ¹ßÇÑ °øµ¿°³¹ß °Å·¡ ¸ÞÀÌÄ¿ ±â¾÷ Áß »óÀ§ 25°³»çÀÇ Á¾ÇÕÀûÀÎ ¸®½ºÆ®¸¦ Á¦°øÇÕ´Ï´Ù. °¢ °Å·¡ Á¦¸ñÀº Current Agreements deals and alliancesÀÇ µ¥ÀÌÅͺ£À̽º¸¦ ÅëÇØ °Å·¡ ±â·ÏÀÇ Àüü ¿Â¶óÀÎ ¹öÀü¿¡ ¸µÅ©µÇ¾î ÀÖÀ¸¸ç, °¡´ÉÇÑ °æ¿ì ½ÇÁ¦ °è¾à ¹®¼­¿¡µµ ¸µÅ©µÇ¾î ÀÖ¾î, °¢ °Å·¡ ±â·Ï¿¡ ¿Âµð¸Çµå ¹æ½ÄÀ¸·Î ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù.

6Àå¿¡¼­´Â 2016³â ÀÌÈÄ Ã¼°á/¹ßÇ¥µÈ °øµ¿°³¹ß °è¾à¼­¸¦ °è¾à¼­°¡ ÀÔ¼ö °¡´ÉÇÑ °æ¿ì, ±â¾÷ A-Z, Ä¡·áÁ¦, ±â¼ú, ¾÷Á¾º°·Î Á¤¸®ÇÏ¿© Æ÷°ýÀûÀÌ°í »ó¼¼ÇÏ°Ô °ËÅäÇϰí ÀÖ½À´Ï´Ù. °è¾à¼­¿¡´Â °øµ¿°³¹ß°ú °ü·ÃÇÏ¿© ´ç»çÀÚ °£¿¡ ÇÕÀÇµÈ ½ÇÁ¦ °Å·¡ Á¶°Ç¿¡ ´ëÇÑ »ó¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

°Å·¡ µð·ºÅ丮¿¡´Â 2016³â ÀÌÈÄ ¹ßÇ¥µÈ ¸ðµç °øµ¿°³¹ß °Å·¡¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¸ñ·ÏÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. °¢ ¸ñ·ÏÀº ±â¾÷ A-Z, Ä¡·á ¿µ¿ª, ±â¼ú À¯Çüº°·Î °Å·¡ µð·ºÅ丮·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. °¢ °Å·¡ Á¦¸ñÀº ÇÏÀÌÆÛ¸µÅ©¸¦ ÅëÇØ °¡´ÉÇÑ °æ¿ì ½ÇÁ¦ °è¾à ¹®¼­¸¦ Æ÷ÇÔÇÑ °Å·¡ ±â·ÏÀÇ ¿Â¶óÀÎ ¹öÀüÀ¸·Î ¿¬°áµË´Ï´Ù.

º» º¸°í¼­¿¡´Â 2016³â ÀÌÈÄ °øµ¿°³¹ß °Å·¡ ¸ÞÀÌÅ·ÀÇ µ¿Çâ°ú Ȱµ¿À» º¸¿©ÁÖ´Â ´Ù¼öÀÇ µµÇ¥°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

°á·ÐÀûÀ¸·Î, º» º¸°í¼­´Â °øµ¿°³¹ß Á¦ÈÞ¿¡ ´ëÇØ ¹Ì·¡ÀÇ °Å·¡¾÷ü°¡ ¾Ë¾Æ¾ß ÇÒ ¸ðµç °ÍÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼Ò°³

Á¦2Àå °øµ¿°³¹ß °Å·¡ µ¿Çâ

Á¦3Àå °øµ¿°³¹ß °Å·¡ ±¸Á¶ °³¿ä

Á¦4Àå °øµ¿°³¹ß °Å·¡ ÁÖµµ

Á¦5Àå °¡Àå Ȱ¹ßÇÑ °øµ¿°³¹ß °Å·¡ Á¦Á¶¾÷ü ÁÖ¿ä 25°³»ç

Á¦6Àå °è¾à µð·ºÅ丮¸¦ Æ÷ÇÔÇÑ °øµ¿°³¹ß °Å·¡

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.

Fully revised and updated, the report provides details of co-development deals from 2016 to 2025.

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals.

Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.

The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.

Key benefits

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Report scope

Co-development Deals in Pharmaceuticals and Biotechnology includes:

In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

Analyzing contract agreements allows due diligence of:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking

Chapter 3 - Overview of co-development deal structure

Chapter 4 - Leading co-development deals

Chapter 5 - Top 25 most active co-development dealmakers

Chapter 6 - Co-development deals including contracts directory

TABLE OF FIGURES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â